Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GLI1 | P08151 | 1/20 | 0.40 |
| ▸ | GLI2 | P10070 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79973 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL3438794 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL17962954 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL11070476 | 0.78 | CYP3A4 (0.43) | CYP3A4GLI1GLI2 | |
| Alpha-Humulone SCHEMBL23460398 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL106386 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL31668762 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL29422612 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL23781774 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL17629686 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027218-A1 | METHOD FOR IMPROVING THE CULTIVATION OF PLANTS UNDER ABIOTIC STRESS CONDITIONS | TIMAC AGRO ESPAÑA, S.A., (ES) | 2025-02-06 | — | — | WO | claimed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| US-8129569-B2 | Photolabile fragrance storage substances | HENKEL AG & CO. KGAA (DE) | 2012-03-06 | — | — | US | claimed |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | HENKEL AG & CO. KGAA (DE) | 2011-02-03 | — | — | US | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124219-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION | SRIN THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12440501-B2 | Cannabinoid compositions and methods of use thereof for immune modulation | SRIN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025090945-A1 | FORMULATIONS HAVING A GLYCOSIDE AND A LIPOPHILIC COMPONENT | SPOKE SCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025027218-A1 | METHOD FOR IMPROVING THE CULTIVATION OF PLANTS UNDER ABIOTIC STRESS CONDITIONS | TIMAC AGRO ESPAÑA, S.A., (ES) | 2025-02-06 | — | — | WO | disclosed |
| EP-4440556-A2 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | Spoke Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-10806707-B2 | Cannabis oil compositions and methods for preparation thereof | CONSTANCE THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10406186-B2 | Cannabis oil extracts and compositions | CONSTANCE THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10238745-B2 | Cannabinoid composition and products including α-tocopherol | CONSTANCE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180344661-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180125980-A1 | CANNABINOID COMPOSITION AND PRODUCTS INCLUDING ALPHA-TOCOPHEROL | CONSTANCE THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160346339-A1 | METHODS FOR PREPARATION OF CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-8129569-B2 | Photolabile fragrance storage substances | HENKEL AG & CO. KGAA (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | HENKEL AG & CO. KGAA (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | CYP3A4 1397/4885GLI1 2872/4885GLI2 4676/4885 |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | NAPEPLD, CNR1, CNR2 | CYP3A4 1401/4885GLI1 2410/4885GLI2 4316/4885 |
| US-20180125980-A1 | CANNABINOID COMPOSITION AND PRODUCTS INCLUDING ALPHA-TOCOPHEROL | TTPA, CNR1, ECH1 | CYP3A4 1105/4885GLI1 1704/4885GLI2 4696/4885 |
| US-20160346339-A1 | METHODS FOR PREPARATION OF CANNABIS OIL EXTRACTS AND COMPOSITIONS | CNR2, CNR1, EPHX2 | CYP3A4 1364/4885GLI1 2842/4885GLI2 4618/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CYP3A4 1822/4885GLI1 4243/4885GLI2 3805/4885 |
| US-10406186-B2 | Cannabis oil extracts and compositions | CNR2, CNR1, DNER | CYP3A4 1613/4885GLI1 2788/4885GLI2 4675/4885 |
| US-20260124219-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION | DEGS1, CNR2, CNR1 | CYP3A4 1401/4885GLI1 3403/4885GLI2 3757/4885 |
| US-20180344661-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | CYP3A4 1397/4885GLI1 2872/4885GLI2 4676/4885 |
| US-10806707-B2 | Cannabis oil compositions and methods for preparation thereof | CNR1, CNR2, PROC | CYP3A4 1397/4885GLI1 2872/4885GLI2 4676/4885 |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | TRPA1, NISCH, TRPV1 | CYP3A4 177/4885GLI1 3545/4885GLI2 4490/4885 |
| US-10238745-B2 | Cannabinoid composition and products including α-tocopherol | TTPA, CNR1, ECH1 | CYP3A4 1028/4885GLI1 1700/4885GLI2 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.